Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16310710 | 0.81 | KDM1A (0.45) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL17848844 | 0.80 | KDM1A (0.41) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL18783062 | 0.80 | KDM1A (0.41) | KDM1AKDM1BRIPK1DPP4 | |
| SCHEMBL17848842 | 0.80 | KDM1A (0.41) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL24200680 | 0.77 | KDM1A (0.39) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL21313092 | 0.76 | SCN9A (0.44) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL21313058 | 0.76 | SCN9A (0.44) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL22013223 | 0.75 | TRPA1 (0.44) | KDM1AKDM1BRIPK1TRPA1DPP4 | |
| SCHEMBL4294177 | 0.75 | KDM1A (0.44) | KDM1AKDM1BRIPK1 | |
| SCHEMBL20016164 | 0.75 | KDM1A (0.44) | KDM1AKDM1BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | KDM1A 4285/4885KDM1B 4029/4885RIPK1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.